Bavarian Nordic closes enrolment for Phase III study of smallpox vaccines

Biopharmaceutical firm Bavarian Nordic has completed enrolment for its Phase III study of smallpox vaccines, IMVAMUNE and ACAM2000.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news